ReviewArchives of women's mental health2017
Treatment options for hyperemesis gravidarum.
Review in Archives of women's mental health, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05452174 (Endeavor to Stop Nausea/Vomiting Associated With Pregnancy), which is not on this map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Endeavor to Stop Nausea/Vomiting Associated With Pregnancy (E-SNAP)
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 62 citations in OpenAlex.
- A Systematic Patent Review (2008-2023) for Treatment in Pregnancy.Current medicinal chemistry · 2024Pooled it
- Hyperemesis Gravidarum and the Genetics of Growth Differentiation Factor 15 (GDF-15): A Case Report.Cureus · 2026Article
- Hyperemesis gravidarum revisited: from GDF15 biology to precision multimodal therapy.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- The Serum Platelet-Albumin Ratio in Hyperemesis Gravidarum: A Retrospective Comparative Study.International journal of women's health · 2026Article
- Associations of Nausea and Vomiting of Pregnancy with Maternal and Fetal Outcomes.Journal of clinical medicine · 2025Article
- GDF15 Targeting for Treatment of Hyperemesis Gravidarum.Medicines (Basel, Switzerland) · 2024Article
- The hyperemesis gravidarum and pulmonary embolism: A case report and review of literature.Qatar medical journal · 2024Article
- Mirtazapine exposure in pregnancy and fetal safety: A nationwide cohort study.Acta psychiatrica Scandinavica · 2022Article
- Use of Mirtazapine and Olanzapine in the Treatment of Refractory Hyperemesis Gravidarum: A Case Report and Systematic Review.Case reports in obstetrics and gynecology · 2022Article
- When is parenteral nutrition indicated?Journal of intensive medicine · 2022Review
- Thyroid-stimulating hormone and free thyroxine fail to predict the severity and clinical course of hyperemesis gravidarum: A prospective cohort study.Acta obstetricia et gynecologica Scandinavica · 2021Article
- Supportive medication in cancer during pregnancy.BMC pregnancy and childbirth · 2020Review
- Article
- Women's perspectives on the management and consequences of hyperemesis gravidarum - a descriptive interview study.Scandinavian journal of primary health care · 2019Article
- Pityriasis rosea-like eruption associated with ondansetron use in pregnancy.British journal of clinical pharmacology · 2018Article
- Mirtazapine for Severe Nausea and Vomiting During Pregnancy: Case Presentations and Recommendations.Journal of clinical psychopharmacologyArticle
- Extended release granisetron: Review of pharmacologic considerations and clinical role in the perioperative setting.Saudi journal of anaesthesiaReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Hyperemesis gravidarum (HG) is a severe and prolonged form of nausea and/or vomiting during pregnancy. HG affects 0.3-2% of pregnancies and is defined by dehydration, ketonuria, and more than 5% body weight loss. Initial pharmacologic treatment for HG includes a combination of doxylamine and pyridoxine. Additional interventions include ondansetron or dopamine antagonists such as metoclopramide or promethazine. The options are limited for women who are not adequately treated with these medications. We suggest that mirtazapine is a useful drug in this context and its efficacy has been described in case studies. Mirtazapine acts on noradrenergic, serotonergic, histaminergic, and muscarinic receptors to produce antidepressant, anxiolytic, antiemetic, sedative, and appetite-stimulating effects. Mirtazapine is not associated with an independent increased risk of birth defects. Further investigation of mirtazapine as a treatment for HG holds promise to expand treatment options for women suffering from HG.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.